Bayesian Capital Management’s Innoviva INVA Stock Holding History

Bayesian Capital Management’s Portfolio INVA Stock Details INVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-14,500	Closed	-$280K	–	832
2024 Q3	$280K	Buy	+14,500	New	+$267K	0.03%	492
2022 Q3	–	Sell	-13,600	Closed	-$201K	–	853
2022 Q2	$201K	Sell	13,600 -4,700	-26%	-$77K	0.04%	623
2022 Q1	$354K	Buy	+18,300	New	+$327K	0.05%	474
2018 Q2	–	Sell	-11,820	Closed	-$197K	–	652
2018 Q1	$197K	Buy	+11,820	New	+$182K	0.05%	508
2017 Q4	–	Sell	-13,500	Closed	-$191K	–	625
2017 Q3	$191K	Buy	+13,500	New	+$178K	0.05%	431
2016 Q2	–	Sell	-15,385	Closed	-$194K	–	471
2016 Q1	$194K	Buy	+15,385	New	+$169K	0.18%	274

Other funds holding INVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bayesian Capital Management's INVA Position: Q4 2024 in Review

Bayesian Capital Management sold out of Innoviva (INVA) in Q4 2024, closing a stake of 14,500 shares — an estimated $280K sold.

Bayesian Capital Management first reported a position in INVA in Q1 2016 and held it in 6 quarters. The position peaked at $354K in Q1 2022. 235 funds tracked by Wall St. Rank hold INVA as of Q4 2024.

Bayesian Capital Management reported no remaining Innoviva position as of Q4 2024 after selling out during the quarter.
Bayesian Capital Management sold 14,500 Innoviva shares in Q4 2024, an estimated $280K.
Bayesian Capital Management first reported a position in Innoviva in Q1 2016 and held it in 6 quarters.
Bayesian Capital Management's Innoviva position peaked at $354K in Q1 2022.
235 funds tracked by Wall St. Rank held Innoviva as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.